Rising Legal Exposure for Ultra-Processed Food Manufacturers Amid New Government-Led Lawsuits: Swiss Re

Key Takeaways

• First government lawsuit against UPF manufacturers filed Dec 2025.
• Plaintiffs shift from individual injury to public cost recovery claims.
• Lack of universal UPF definition hampers legal causation arguments.
• Discovery of internal documents could raise settlement pressure.
• Successful rulings may spark worldwide follow‑on UPF lawsuits.

Summary

Swiss Re's sigma insights report warns that ultra‑processed food (UPF) makers face growing legal exposure after the first government‑initiated lawsuit was filed in December 2025. Plaintiffs are expanding tactics from individual injury claims to public‑cost recovery actions that sidestep strict causation proof, leveraging theories such as unfair competition and public nuisance. The analysis highlights challenges including the absence of a universally accepted UPF definition and reliance on observational studies, which could affect litigation outcomes. If a case succeeds, it could create momentum for similar actions across multiple jurisdictions, raising potential defense costs and settlement liabilities for manufacturers.

Pulse Analysis

The rise of ultra‑processed foods has become a defining feature of diets in high‑income economies, with recent data showing that more than half of daily calories in the United States and United Kingdom come from these products. Health researchers link high UPF consumption to obesity, diabetes, and cardiovascular disease, prompting governments to scrutinize the sector. While scientific consensus is still forming, the sheer scale of exposure—especially among children, who obtain roughly 62 % of their calories from UPFs—has turned the category into a public‑health flashpoint.

Against this backdrop, Swiss Re’s latest sigma insights report documents a watershed moment: the first government‑sponsored lawsuit against UPF manufacturers filed in December 2025. Plaintiffs are moving beyond traditional personal‑injury claims, employing public‑cost recovery theories that argue manufacturers’ products impose undue burdens on healthcare systems. By framing the dispute as an unfair‑competition or public‑nuisance issue, litigants aim to bypass the stringent causation standards that have limited earlier cases. The lack of a universally accepted definition of ‘ultra‑processed’ and the reliance on observational studies further complicate the evidentiary landscape, creating both opportunities and uncertainties for defendants.

The potential ripple effects are significant for food conglomerates, insurers, and investors. A favorable ruling for plaintiffs could set a precedent that encourages parallel actions in Europe, Asia and Latin America, inflating defense costs and prompting companies to reevaluate product formulations, labeling, and marketing practices. Insurers are likely to adjust underwriting criteria, pricing cyber‑style liability coverage for the sector. Meanwhile, boardrooms may face pressure to enhance transparency around supply chains and to fund independent research that can withstand courtroom scrutiny. Monitoring regulatory trends and early case developments will be essential for managing emerging financial exposure.